期刊文献+

基于NMR指纹谱相关分析的生物类似药高级结构评价(英文)

Higher Order Structure Assessment of Biosimilars Based on the Correlation of NMR Spectral Fingerprints
下载PDF
导出
摘要 建立了基于1H NMR指纹技术的生物类似药高级结构相似性分析方法,利用相关系数r和决定系数R2定量评估生物类似药与其原研药的结构相似度.将该方法应用在一种分子量为1 620的抗菌性脂肽达托霉素上,比较了其类似药的活性原料成分(API)、类似药制剂与原研药克必信的高级结构相似性.实验结果显示,3个达托霉素样品的谱图存在显著差异,表明达托霉素类似药与其原研药在水溶液中存在结构差异.将该方法应用在分子量为145 423的单克隆抗体药物曲妥珠单抗的高级结构比对上.对1个批次的赫赛汀原研药、4个批次的类似药的1H NMR谱进行相似性分析,相关系数r和决定系数R2的结果显示,曲妥珠单抗的类似药与赫赛汀原研药相似度很高;进一步采用局部相关系数进行谱图分析,得到了曲妥珠单抗类似药与赫赛汀原研药之间的微小差异.研究表明,有效结合NMR指纹分析技术和统计分析方法,将在生物类似药质量控制中发挥重大的作用. A procedure based on the1H NMR fingerprints of biologics was established for the assessment of higher order structure of biosimilar samples. The global correlation coefficientsr andR2 of binned NMR spectra were used to quantify structural similarity between biosimilars and originators, and a local correlation analysis method was used to find out the specific regions that contribute to the structure differences. This method was applied to the quantitative assessment of daptomycin, a lipopeptide antibiotic with a molecular weight of 1 620, by comparing the higher order structure of the biosimilar active pharmaceutical ingredient (API), its injection and originator injection Cubicin. The results showed that there were significant spectral differences among daptomycin samples, indicating structural differences between daptomycin originator and its biosimilars. Local correlation analysis further revealed the specific spectral regions that contributed to these differences. The method was also applied to a monoclonal antibody drug Trastuzumab, which is a large protein with a molecular weight of 145 423.1H NMR spectra of the originator drug Herceptin and four lots of its biosimilar were recorded and binned for statistical analysis. The correlation coefficientsr andR2 showed that Trastuzumab biosimilars seem to be highly similar to Herceptin. These results demonstrated that the combination of NMR fingerprints and statistical analysis is a powerful and robust technique in biosimilar quality control.
出处 《波谱学杂志》 CAS CSCD 北大核心 2015年第2期342-353,共12页 Chinese Journal of Magnetic Resonance
基金 The National Science and Technology Major Projects(2014ZX09304311-001,2012ZX09301003-001-010)
关键词 NMR指纹技术 生物类似药 相似度评价 高级结构 NMR fingerprint biosimilar similarity assessment higher order structure
  • 引文网络
  • 相关文献

参考文献16

  • 1Walsh G. Biopharmaceutical benchmarks 2014[J]. Nat Biotech, 2014, 32(10): 992- 1 000.
  • 2European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing monoclonal antibodies-non-clinical and clinical issues[OL]. London: European Medicines Agency; 2012. http://www.ema.eurpa.eu/dcs/enGB/dcumentibrary/Scienticguideine/202/06/wC50028686.pdf.
  • 3Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry. Scientific considerations in demonstrating biosimilarity to a reference product[OL]. Rockville: Food and Drug Administration; 2012. http://www.fda.gv/dwnads/Drugs/GuidanceCmpianceReguatryInfrmatin/Guidances/UCM291128.pdf. Berkowitz S A, Engen J R, Mazzeo J R, et al. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars[J]. Nat Rev Drug Discov, 2012, 11(7): 527-540.
  • 4Berkowitz S A, Engen J R, Mazzeo J R, et al. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars[J]. Nat Rev Drug Diseov, 2012, 11(7): 527-540.
  • 5Falconer R J, Jackson-Matthews D, Mahler S M. Analytical strategies for assessing comparability of biosimilars[J]. J Chem Yechnol Biotechnol, 2011, 86(7): 915-922.
  • 6Federici M, Lubiniecki A, Manikwar P, et al. Analytical lessons learned from selected therapeutic protein drug comparability studies[J]. Biologicals, 2013, 41(3): 131 -147.
  • 7Houde D, Berkowitz S A, Engen J R. The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies[J]. J Pharm Sci, 2011,100(6): 2 071 -2 086.
  • 8Amezcua C A, Szabo C M. Assessment of higher order structure comparability in therapeutic proteins using nuclear magnetic resonance spectroscopy[J]. J Pharm Sci, 2013, 102(6): 1 724- 1 733.
  • 9Wishart D S. Characterization of biopharmaceuticals by NMR spectroscopy[J]. TrAC-Trends Anal Chem, 2013, 48: 96- 111.
  • 10Quintemet M, Starck J P, Delsuc M A, et al. Heteronuclear NMR provides an accurate assessment of therapeutic insulin's quality[J]. J Pharm Biomed Anal, 2013, 78/79: 252-254.
;
使用帮助 返回顶部